The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 30, 2020

Filed:

Dec. 18, 2018
Applicant:

Nanopharmaceuticals, Llc, Rensselaer, NY (US);

Inventors:

Shaker A. Mousa, Wynantskill, NY (US);

Mehdi Rajabi, Albany, NY (US);

Assignee:

NANOPHARMACEUTICALS, LLC, Renesselaer, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/60 (2017.01); A61K 47/61 (2017.01); A61K 47/69 (2017.01); A61K 47/54 (2017.01); A61K 31/19 (2006.01);
U.S. Cl.
CPC ...
A61K 47/60 (2017.08); A61K 31/19 (2013.01); A61K 47/545 (2017.08); A61K 47/61 (2017.08); A61K 47/6957 (2017.08);
Abstract

Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward and classified as anti-angiogenic thyrointegrin antagonists, which may be capable of reacting with one or more cell surface receptors of the integrin αvβ3 receptor family. Anti-angiogenic thyrointegrin antagonists or derivatives thereof are conjugated via a non-cleavable linker having an amine, diamine or triazole linkage to polymers of Polyethylene Glycol, cyclodextrin, chitosan, alginic acid or hyaluronic acid, forming a single chemical entity. Utility of the compositions disclosed may treat angiogenesis-mediated disorders such as Cancer (Solid tumors and Liquid tumors), ocular disorders (Diabetic Retinopathy and Age-related Macular Degeneration), inflammatory disorders (arthritis, osteoarthritis), atherosclerosis, lesions, and dermatology (Rosacea, Psoriasis, skin cancer) and diseases mediated or dependent upon the generation of new blood cells via angiogenesis to persist and the treatment thereof or dependent on antagonizing the formation of new blood vessels to slow or eliminate angiogenic pathways.


Find Patent Forward Citations

Loading…